News
1d
Clinical Trials Arena on MSNRoche and Genentech’s Lunsumio-Polivy shows promise in Phase III trialRoche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...
Those adjustments just keep coming. As SFGATE reported, Genentech announced 436 layoffs in April 2024, and 93 more layoffs ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...
Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...
Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco. | Genentech ...
After enduring multiple rounds of layoffs last year, Genentech’s employees are facing more uncertainty as the Roche unit lets ...
Genentech is planning cuts on the Peninsula.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall ...
Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, ...
Genentech will close its cancer immunology research department, and unit head and renowned cell biologist Ira Mellman, who has been with the company for 17 years, will depart in the coming months.
How Genentech and other drug makers are stepping up the game in how they interact with patients. As Sawsan Zakaria and other spinal muscular atrophy patients made their way along the fashion show ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. For decades, the biotech company Genentech has carved out a reputation in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results